VNRX vs GKOS vs EXAS vs ATRC

For growth investors, VolitionRx Limited (VNRX) is the stronger pick with 40.

0% revenue growth year-over-year, versus 14. 9% for AtriCure, Inc. (ATRC). Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.

5%, compared to -96. 1% for VolitionRx Limited (VNRX). Over 10 years, the gap is even starker: EXAS returned +1669% versus VNRX's -96. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

05β versus Glaukos Corporation's 1. 16β — meaning GKOS is approximately 2106% more volatile than EXAS relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), VolitionRx Limited (VNRX) is pulling ahead at 40.

0% versus 14. 9% for AtriCure, Inc. (ATRC). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, VNRX leads at 78. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AtriCure, Inc.

(ATRC) is the more profitable company, earning -2. 1% net margin versus -1352. 2% for VolitionRx Limited — meaning it keeps -2. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ATRC leads at -0. 6% versus -1228. 6% for VNRX. At the gross margin level — before operating expenses — VNRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AtriCure, Inc.

(ATRC) trades at 428. 7x forward P/E versus 582. 8x for Exact Sciences Corporation — 154. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 84. 6% to $51. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, ATRC: +84. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VNRX is a small-cap high-growth stock; GKOS is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; ATRC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.